Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Virax Biolabs Group Limited

Market Cap 3.53M 3.05M 2.81M 2.63M 4.91M 336M 5.02M 33.43M 12.96M 163M 13.24M 12.95M 566M P/E ratio 2026 *
-0.44x
P/E ratio 2027 * -0.74x
Enterprise value 3.53M 3.05M 2.81M 2.63M 4.91M 336M 5.02M 33.43M 12.96M 163M 13.24M 12.95M 566M EV / Sales 2026 *
882x
EV / Sales 2027 * 882x
Free-Float
98.21%
Yield 2026 *
-
Yield 2027 * -
1 day-5.95%
1 week-26.28%
Current month-6.40%
1 month+3.51%
3 months-12.64%
6 months-63.80%
Current year-48.81%
1 week 0.17
Extreme 0.1715
0.21
1 month 0.13
Extreme 0.13
0.53
Current year 0.1
Extreme 0.1
0.53
1 year 0.1
Extreme 0.1
1.14
3 years 0.1
Extreme 0.1
9
5 years 0.1
Extreme 0.1
290
10 years 0.1
Extreme 0.1
290
Manager TitleAgeSince
Chief Executive Officer 40 31/12/2012
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer 61 31/08/2023
Director TitleAgeSince
Chairman 40 31/12/2012
Director/Board Member 51 -
Director/Board Member 61 -
Date Insider Type Main position Quantity % Market Cap.
03-17Other

Chief Operating Officer

120,000 1.6165%
03-17Other

Director

32,000 0.4311%
03-17Other

Director

32,000 0.4311%
Change 5-day change 1-year change 3-year change Capi.($)
-5.95%-26.28%-82.30%-95.84% 3.53M
+0.75%+2.07%-13.46%-11.34% 43.68B
-3.58%-7.56%+243.47%+464.57% 30.65B
-2.19%+0.07%+14.02%-11.82% 30.4B
-1.70%-5.52%+0.07%+22.02% 29.31B
-1.59%-6.51%+8.30%+13.51% 24.2B
-0.23%+3.31%+52.25%+124.06% 13.3B
-1.61%-3.23% - - 13.03B
+0.68%+5.89%+11.22%+9.36% 13.21B
-1.69%-0.68%+99.02%+80.37% 12.12B
Average -1.71%-3.71%+36.96%+66.10% 20.99B
Weighted average by Cap. -1.27%-1.69%+48.50%+86.89%

Financials

2026 *2027 *
Net sales 4K 3.46K 3.19K 2.99K 5.57K 381K 5.7K 37.92K 14.71K 185K 15.02K 14.69K 642K 4K 3.46K 3.19K 2.99K 5.57K 381K 5.7K 37.92K 14.71K 185K 15.02K 14.69K 642K
Net income -4.94M -4.28M -3.94M -3.69M -6.88M -471M -7.04M -46.85M -18.17M -228M -18.55M -18.15M -793M -5.2M -4.5M -4.15M -3.88M -7.24M -495M -7.4M -49.27M -19.11M -240M -19.51M -19.09M -834M
Net Debt - -
Logo Virax Biolabs Group Limited
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
Employees
19
Date Price Change Volume
10/06/26 0.1770 $ -5.95% 1,010,055
09/06/26 0.1882 $ -9.87% 1,250,273
08/06/26 0.2088 $ -1.74% 823,867
05/06/26 0.2125 $ +7.27% 1,683,998
04/06/26 0.1981 $ -17.49% 2,939,718
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1770USD
Average target price
1.000USD
Spread / Average Target
+464.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VRAX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!